losartan has been researched along with Alveolitis, Fibrosing in 16 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Paraquat (PQ) is one of the most widely used herbicides in the world and can cause pulmonary fibrosis in the cases with intoxication." | 7.81 | Losartan attenuates paraquat-induced pulmonary fibrosis in rats. ( Guo, F; Hu, XT; Li, J; Li, S; Liu, ZF; Su, L; Sun, YB, 2015) |
| "Twenty-four male Wistar rats were randomized into pulmonary fibrosis model, perindopril treatment, losartan treatment and control groups." | 7.74 | [Perindopril and losartan attenuate bleomycin A5-induced pulmonary fibrosis in rats]. ( Cai, SX; Cheng, YX; Li, X; Meng, Y; Tong, WC, 2008) |
| " This study aimed to explore the effect of losartan, an angiotensin II type 1 receptor antagonist, on lung fibrosis in neonatal rats with hyperoxia-induced chronic lung disease (CLD) and its possible mechanisms." | 7.74 | [Effect of losartan on lung fibrosis in neonatal rats with hyperoxia-induced chronic lung disease]. ( Chen, N; Li, JJ; Xue, XD, 2007) |
| "To study the effect of losartan, an angiotensin II antagonist, on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism." | 7.73 | Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. ( Lu, Y; Yao, HW; Zhao, MH; Zhu, JP, 2006) |
| "To study the effect of losartan on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism." | 7.71 | [Losartan in the rat model of bleomycin-induced pulmonary fibrosis and its impact on the expression of monocyte chemoattractant protein-1 and basic fibroblast growth factor]. ( Fang, X; Hu, X; Liu, Y; Zhu, Y, 2002) |
| "Paraquat (PQ) is one of the most widely used herbicides in the world and can cause pulmonary fibrosis in the cases with intoxication." | 3.81 | Losartan attenuates paraquat-induced pulmonary fibrosis in rats. ( Guo, F; Hu, XT; Li, J; Li, S; Liu, ZF; Su, L; Sun, YB, 2015) |
| "Twenty-four male Wistar rats were randomized into pulmonary fibrosis model, perindopril treatment, losartan treatment and control groups." | 3.74 | [Perindopril and losartan attenuate bleomycin A5-induced pulmonary fibrosis in rats]. ( Cai, SX; Cheng, YX; Li, X; Meng, Y; Tong, WC, 2008) |
| " This study aimed to explore the effect of losartan, an angiotensin II type 1 receptor antagonist, on lung fibrosis in neonatal rats with hyperoxia-induced chronic lung disease (CLD) and its possible mechanisms." | 3.74 | [Effect of losartan on lung fibrosis in neonatal rats with hyperoxia-induced chronic lung disease]. ( Chen, N; Li, JJ; Xue, XD, 2007) |
| "To study the effect of losartan, an angiotensin II antagonist, on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism." | 3.73 | Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. ( Lu, Y; Yao, HW; Zhao, MH; Zhu, JP, 2006) |
| "To study the effect of losartan on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism." | 3.71 | [Losartan in the rat model of bleomycin-induced pulmonary fibrosis and its impact on the expression of monocyte chemoattractant protein-1 and basic fibroblast growth factor]. ( Fang, X; Hu, X; Liu, Y; Zhu, Y, 2002) |
| "Paricalcitol treatment suppressed the induction of these RAS components, whereas vitamin D deficiency enhanced the activation of the lung RAS." | 1.62 | Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin-angiotensin system in the lung. ( Chang, J; Du, J; Ge, X; Li, X; Li, YC; Liu, W; Nie, H; Sun, Y; Wei, X; Xun, Z, 2021) |
| "Vitamin D deficiency is associated with pulmonary fibrosis and impaired lung function, but the underlying mechanism has not yet been fully elucidated." | 1.46 | Chronic vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system. ( Fu, J; Liu, T; Shi, Y; Xing, Y; Xue, X; Yao, L; Zhao, X, 2017) |
| "Losartan (10 mg/kg) was administered by gavage daily, starting from 1 d before LPS stimulation." | 1.39 | Angiotensin-(1-7) attenuates lung fibrosis by way of Mas receptor in acute lung injury. ( Chen, Q; Huang, Y; Liu, L; Pan, C; Qiu, H; Yang, Y, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (68.75) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, J | 1 |
| Nie, H | 1 |
| Ge, X | 1 |
| Du, J | 1 |
| Liu, W | 1 |
| Li, X | 4 |
| Sun, Y | 1 |
| Wei, X | 1 |
| Xun, Z | 1 |
| Li, YC | 1 |
| Shi, Y | 1 |
| Liu, T | 1 |
| Yao, L | 1 |
| Xing, Y | 1 |
| Zhao, X | 1 |
| Fu, J | 1 |
| Xue, X | 1 |
| Chen, Q | 1 |
| Yang, Y | 1 |
| Huang, Y | 1 |
| Pan, C | 1 |
| Liu, L | 1 |
| Qiu, H | 1 |
| Guo, F | 1 |
| Sun, YB | 1 |
| Su, L | 1 |
| Li, S | 1 |
| Liu, ZF | 1 |
| Li, J | 2 |
| Hu, XT | 1 |
| Meng, Y | 2 |
| Cai, SX | 1 |
| Tong, WC | 1 |
| Cheng, YX | 1 |
| Chou, HC | 1 |
| Lang, YD | 1 |
| Wang, LF | 1 |
| Wu, TY | 1 |
| Hsieh, YF | 1 |
| Chen, CM | 1 |
| Fang, X | 1 |
| Zhu, Y | 1 |
| Hu, X | 1 |
| Liu, Y | 1 |
| Uhal, BD | 3 |
| Wang, R | 2 |
| Laukka, J | 1 |
| Zhuang, J | 2 |
| Soledad-Conrad, V | 1 |
| Filippatos, G | 1 |
| Marshall, RP | 1 |
| Gohlke, P | 1 |
| Chambers, RC | 1 |
| Howell, DC | 1 |
| Bottoms, SE | 1 |
| Unger, T | 1 |
| McAnulty, RJ | 1 |
| Laurent, GJ | 1 |
| Rayford, H | 1 |
| Keogh, KA | 1 |
| Standing, J | 1 |
| Kane, GC | 1 |
| Terzic, A | 1 |
| Limper, AH | 1 |
| Yao, HW | 1 |
| Zhu, JP | 1 |
| Zhao, MH | 1 |
| Lu, Y | 1 |
| Molina-Molina, M | 1 |
| Serrano-Mollar, A | 1 |
| Bulbena, O | 1 |
| Fernandez-Zabalegui, L | 1 |
| Closa, D | 1 |
| Marin-Arguedas, A | 1 |
| Torrego, A | 1 |
| Mullol, J | 1 |
| Picado, C | 1 |
| Xaubet, A | 1 |
| Long, X | 1 |
| Xiong, SD | 1 |
| Xiong, WN | 1 |
| Xu, YJ | 1 |
| Zhang, ZX | 1 |
| Cao, Y | 1 |
| Chen, J | 1 |
| Xu, XH | 1 |
| Chen, N | 1 |
| Li, JJ | 1 |
| Xue, XD | 1 |
| Papp, M | 1 |
16 other studies available for losartan and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin-angiotensin system in the lung.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Bleomycin; Diseas | 2021 |
Chronic vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system.
Topics: Amides; Animals; Blood Pressure; Chronic Disease; Extracellular Matrix; Female; Fumarates; Losartan; | 2017 |
Angiotensin-(1-7) attenuates lung fibrosis by way of Mas receptor in acute lung injury.
Topics: Acute Lung Injury; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; | 2013 |
Losartan attenuates paraquat-induced pulmonary fibrosis in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Collagen; Herbicides; Hydroxypr | 2015 |
[Perindopril and losartan attenuate bleomycin A5-induced pulmonary fibrosis in rats].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Bleomyci | 2008 |
Angiotensin II type 1 receptor antagonist attenuates lung fibrosis in hyperoxia-exposed newborn rats.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Blotting, Western; Body | 2012 |
[Losartan in the rat model of bleomycin-induced pulmonary fibrosis and its impact on the expression of monocyte chemoattractant protein-1 and basic fibroblast growth factor].
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Bleomycin; Chemoki | 2002 |
Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists.
Topics: Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Ant | 2003 |
Angiotensin II and the fibroproliferative response to acute lung injury.
Topics: Acute Disease; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antibiotics, Antineoplastic | 2004 |
Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Bleomycin; Collagen; Gene Deletion; Los | 2003 |
Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Bleomycin; Losartan; Mice; Mice, Inbred C57BL; Pul | 2005 |
Losartan attenuates bleomycin-induced pulmonary fibrosis in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Bleomycin; Body Weigh | 2006 |
Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antimetabolites, Antineoplastic; Bleomycin; Cycloo | 2006 |
[Losartan inhibited angiotensin induced human lung fibroblast transformation and collagen synthesis].
Topics: Angiotensin II; Cell Differentiation; Cells, Cultured; Collagen; Fibroblasts; Humans; Losartan; Pulm | 2007 |
[Effect of losartan on lung fibrosis in neonatal rats with hyperoxia-induced chronic lung disease].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Bronchopulmonary Dysplasia; Huma | 2007 |
Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II.
Topics: Adenocarcinoma; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Apoptosis | 2002 |